164 related articles for article (PubMed ID: 12926151)
1. Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy.
Nather A; Mayerhofer K; Grimm C; Hefler L; Leodolter S; Obermair A; Joura EA
Anticancer Res; 2003; 23(3C):2991-4. PubMed ID: 12926151
[TBL] [Abstract][Full Text] [Related]
2. Thrombocytosis in advanced epithelial ovarian cancer.
Soonthornthum T; Suraseraneewong V; Kengsakol K; Wijaithum K; Kasemsan P; Prommatt S
J Med Assoc Thai; 2007 Aug; 90(8):1495-500. PubMed ID: 17926975
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of anaemia at different treatment times in patients with locally advanced head and neck cancer treated with surgery and postoperative radiotherapy.
Dietl B; Marienhagen J; Schäfer C; Kölbl O
Clin Oncol (R Coll Radiol); 2007 May; 19(4):228-33. PubMed ID: 17433968
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of platelet count in patients with renal cell carcinoma.
Erdemir F; Kilciler M; Bedir S; Ozgok Y; Coban H; Erten K
Urol Int; 2007; 79(2):111-6. PubMed ID: 17851278
[TBL] [Abstract][Full Text] [Related]
5. Thrombocytosis in women with vulvar carcinoma.
Lavie O; Comerci G; Daras V; Bolger BS; Lopes A; Monaghan JM
Gynecol Oncol; 1999 Jan; 72(1):82-6. PubMed ID: 9889035
[TBL] [Abstract][Full Text] [Related]
6. Platelet Count After Chemotherapy is a Predictor for Outcome for Ovarian Cancer Patients.
Eggemann H; Ehricke J; Ignatov T; Fettke F; Semczuk A; Costa SD; Ignatov A
Cancer Invest; 2015 May; 33(5):193-6. PubMed ID: 25831456
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of thrombocytosis in ovarian cancer.
Słabuszewska-Jóźwiak A; Dmoch-Gajzlerska E; Kozakiewicz B; Jakiel G
Ann Agric Environ Med; 2015; 22(4):731-5. PubMed ID: 26706987
[TBL] [Abstract][Full Text] [Related]
8. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.
Suppiah R; Shaheen PE; Elson P; Misbah SA; Wood L; Motzer RJ; Negrier S; Andresen SW; Bukowski RM
Cancer; 2006 Oct; 107(8):1793-800. PubMed ID: 16983701
[TBL] [Abstract][Full Text] [Related]
9. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
10. Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer.
Bozkurt N; Yuce K; Basaran M; Kose F; Ayhan A
Obstet Gynecol; 2004 Jan; 103(1):82-5. PubMed ID: 14704249
[TBL] [Abstract][Full Text] [Related]
11. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
Downs LS; Judson PL; Argenta PA; Ghebre R; Geller MA; Bliss RL; Boente MP; Nahhas WA; Abu-Ghazaleh SZ; Chen MD; Carson LF
Cancer; 2008 Jan; 112(2):331-9. PubMed ID: 18058810
[TBL] [Abstract][Full Text] [Related]
13. [The prognostic value of thrombocytosis in patients with primary lung cancer].
Pedersen LM; Milman N
Ugeskr Laeger; 1998 Jun; 160(26):3917-20. PubMed ID: 9656833
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
[TBL] [Abstract][Full Text] [Related]
15. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K
Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122
[TBL] [Abstract][Full Text] [Related]
16. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
McMeekin DS; Tillmanns T; Chaudry T; Gold M; Johnson G; Walker J; Mannel R
Gynecol Oncol; 2004 Oct; 95(1):157-64. PubMed ID: 15385126
[TBL] [Abstract][Full Text] [Related]
17. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma.
Brockmann MA; Giese A; Mueller K; Kaba FJ; Lohr F; Weiss C; Gottschalk S; Nolte I; Leppert J; Tuettenberg J; Groden C
Neuro Oncol; 2007 Jul; 9(3):335-42. PubMed ID: 17504931
[TBL] [Abstract][Full Text] [Related]
18. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.
Kim YH; Goto K; Yoh K; Niho S; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Cancer; 2008 Nov; 113(9):2518-23. PubMed ID: 18780323
[TBL] [Abstract][Full Text] [Related]
19. Significance of thrombocytosis in patients with epithelial ovarian cancer.
Zeimet AG; Marth C; Müller-Holzner E; Daxenbichler G; Dapunt O
Am J Obstet Gynecol; 1994 Feb; 170(2):549-54. PubMed ID: 8116711
[TBL] [Abstract][Full Text] [Related]
20. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]